Our Science

Curative therapies for patients with solid tumors is the next major step for adoptive cell therapy (ACT).

Our Approach

Lyell is built on the belief that effective ACT in solid tumors is all about the cells. We are addressing what we believe are the primary barriers that limit consistent, reliable and durable responses to ACT in solid tumors: T-cell exhaustion and lack of durable stemness.

A Lyell employee working with ACT samples

Our Technologies

Solid tumors represent approximately 90% of cancers, but ACTs have demonstrated limited success treating these types of cancer. Lyell is reprogramming T cells designed to outlast and eradicate solid tumors.

Gen-R™

Designed to Delay Exhaustion, Retain Function

Epi-R™

Designed to Create Durable Stemness

Rejuvenation

Designed to Turn Back
the Clock

Epi-R is an ex vivo epigenetic reprogramming technology that generates populations of polyclonal T cells that can proliferate, persist and self-renew, and generate differentiated effector cell progenies to provide durable antitumor functionality. Together, these properties define the characteristics we call durable stemness.

Collaborations

We welcome collaborations with organizations tackling the challenges of developing curative therapies for solid tumors. Contact us at businessdevelopmentlyell.com to explore collaboration opportunities.